These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 3701612)
1. Effect of particle dissolution rate on ocular drug bioavailability. Hui HW; Robinson JR J Pharm Sci; 1986 Mar; 75(3):280-7. PubMed ID: 3701612 [TBL] [Abstract][Full Text] [Related]
2. General Pharmacokinetic Model for Topically Administered Ocular Drug Dosage Forms. Deng F; Ranta VP; Kidron H; Urtti A Pharm Res; 2016 Nov; 33(11):2680-90. PubMed ID: 27431864 [TBL] [Abstract][Full Text] [Related]
3. Volume to dissolve applied dose (VDAD) and apparent dissolution rate (ADR): tools to predict in vivo bioavailability from orally applied drug suspensions. Muenster U; Pelzetter C; Backensfeld T; Ohm A; Kuhlmann T; Mueller H; Lustig K; Keldenich J; Greschat S; Göller AH; Gnoth MJ Eur J Pharm Biopharm; 2011 Aug; 78(3):522-30. PubMed ID: 21315152 [TBL] [Abstract][Full Text] [Related]
4. Application of Mechanistic Ocular Absorption Modeling and Simulation to Understand the Impact of Formulation Properties on Ophthalmic Bioavailability in Rabbits: a Case Study Using Dexamethasone Suspension. Le Merdy M; Fan J; Bolger MB; Lukacova V; Spires J; Tsakalozou E; Patel V; Xu L; Stewart S; Chockalingam A; Narayanasamy S; Rouse R; Matta M; Babiskin A; Kozak D; Choi S; Zhang L; Lionberger R; Zhao L AAPS J; 2019 May; 21(4):65. PubMed ID: 31111305 [TBL] [Abstract][Full Text] [Related]
5. Effect of particle size on ophthalmic bioavailability of dexamethasone suspensions in rabbits. Schoenwald RD; Stewart P J Pharm Sci; 1980 Apr; 69(4):391-4. PubMed ID: 7373531 [TBL] [Abstract][Full Text] [Related]
6. Vehicle effects on ocular drug bioavailability i: evaluation of fluorometholone. Sieg JW; Robinson JR J Pharm Sci; 1975 Jun; 64(6):931-6. PubMed ID: 1133744 [TBL] [Abstract][Full Text] [Related]
8. Topical pharmacokinetics of dexamethasone suspensions in the rabbit eye: Bioavailability comparison. Naageshwaran V; Ranta VP; Toropainen E; Tuomainen M; Gum G; Xie E; Bhoopathy S; Urtti A; Del Amo EM Int J Pharm; 2022 Mar; 615():121515. PubMed ID: 35091006 [TBL] [Abstract][Full Text] [Related]
9. Ocular pharmacokinetics and availability of topically applied baicalein in rabbits. Zhang L; Zhang J; Wang L; Xia H Curr Eye Res; 2009 Apr; 34(4):257-63. PubMed ID: 19373573 [TBL] [Abstract][Full Text] [Related]
10. Biopharmaceutics of Topical Ophthalmic Suspensions: Importance of Viscosity and Particle Size in Ocular Absorption of Indomethacin. Toropainen E; Fraser-Miller SJ; Novakovic D; Del Amo EM; Vellonen KS; Ruponen M; Viitala T; Korhonen O; Auriola S; Hellinen L; Reinisalo M; Tengvall U; Choi S; Absar M; Strachan C; Urtti A Pharmaceutics; 2021 Mar; 13(4):. PubMed ID: 33810564 [TBL] [Abstract][Full Text] [Related]
11. Bioavailability and anticataract effects of a topical ocular drug delivery system containing disulfiram and hydroxypropyl-beta-cyclodextrin on selenite-treated rats. Wang S; Li D; Ito Y; Nabekura T; Wang S; Zhang J; Wu C Curr Eye Res; 2004 Jul; 29(1):51-8. PubMed ID: 15370367 [TBL] [Abstract][Full Text] [Related]
12. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim. Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464 [TBL] [Abstract][Full Text] [Related]
13. Influence of topical anesthesia on tear dynamics and ocular drug bioavailability in albino rabbits. Patton TF; Robinson JR J Pharm Sci; 1975 Feb; 64(2):267-71. PubMed ID: 1127583 [TBL] [Abstract][Full Text] [Related]
14. Ocular pharmacokinetics of topically-applied ketoconazole solution containing hydroxypropyl beta-cyclodextrin to rabbits. Zhang J; Wang L; Gao C; Zhang L; Xia H J Ocul Pharmacol Ther; 2008 Oct; 24(5):501-6. PubMed ID: 18803444 [TBL] [Abstract][Full Text] [Related]
15. A corneal perfusion device for estimating ocular bioavailability in vitro. Richman JB; Tang-Liu DD J Pharm Sci; 1990 Feb; 79(2):153-7. PubMed ID: 2324964 [TBL] [Abstract][Full Text] [Related]
16. Relationship of chemical structure to corneal penetration and influence of low-viscosity solution on ocular bioavailability. Grass GM; Robinson JR J Pharm Sci; 1984 Aug; 73(8):1021-7. PubMed ID: 6491903 [TBL] [Abstract][Full Text] [Related]
17. Formulation, in vitro dissolution, and ocular bioavailability of high- and low-melting phenylephrine oxazolidines. Qiu Y; Guillory JK; Schoenwald RD Pharm Res; 1993 Nov; 10(11):1627-31. PubMed ID: 8290476 [TBL] [Abstract][Full Text] [Related]
18. Penetration of fluorometholone into the cornea and aqueous humor. Kupferman A; Leibowitz HM Arch Ophthalmol; 1975 Jun; 93(6):425-7. PubMed ID: 1131082 [TBL] [Abstract][Full Text] [Related]
19. Corneal absorption of fluorometholone in rabbits. A comparative evaluation of corneal drug transport characteristics in anesthetized and unanesthetized rabbits. Sieg JW; Robinson JR Arch Ophthalmol; 1974 Sep; 92(3):240-3. PubMed ID: 4851189 [No Abstract] [Full Text] [Related]